Theranostics, 1838-7640

Tidskrift

Fler filtreringsmöjligheter
  1. 2019
  2. Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics

    Oskar Vilhelmsson Timmermand, Elgqvist, J., Beattie, K. A., Anders Örbom, Erik Larsson, Sophie E Eriksson, Thorek, D. L. J., Beattie, B. J., Thuy A Tran, David Ulmert & Sven-Erik Strand, 2019, I : Theranostics. 9, 8, s. 2129-2142 14 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  3. 2017
  4. Incremental value of circulating MiR-122-5P to predict outcome after out of hospital cardiac arrest

    Devaux, Y., Salgado-Somoza, A., Josef Dankiewicz, Boileau, A., Stammet, P., Schritz, A., Zhang, L. L., Vausort, M., Patrik Gilje, David Erlinge, Hassager, C., Wise, M. P., Kuiper, M., Hans Friberg, Niklas Nielsen, TTM-trial investigators & On behalf of the Cardiolinc™ network, 2017, I : Theranostics. 7, 10, s. 2555-2564 10 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  5. Limited tumor tissue drug penetration contributes to primary resistance against angiogenesis inhibitors

    Torok, S., Melinda Rezeli, Kelemen, O., Vegvari, A., Watanabe, K., Yutaka Sugihara, Tisza, A., Marton, T., Kovacs, I., Tovari, J., Laszlo, V., Helbich, T. H., Hegedus, B., Klikovits, T., Hoda, M. A., Klepetko, W., Paku, S., Gyorgy Marko-Varga & Dome, B., 2017, I : Theranostics. 7, 2, s. 400-412 13 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  6. 2014
  7. FMN-coated fluorescent USPIO for cell labeling and non-invasive MR imaging in tissue engineering

    Mertens, M., Frese, J., Deniz Ali Bölükbas, Hrdlicka, L., Golombek, S., Koch, S., Mela, P., Jockenhövel, S., Kiessling, F. & Lammers, T., 2014 jul 28, I : Theranostics. 4, 10, s. 1002-13

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift